TY - JOUR
T1 - Randomized trial of the quantitative and functional antibody responses to a 7-valent pneumococcal conjugate vaccine and/or 23-valent polysaccharide vaccine among HIV-infected adults
AU - Feikin, Daniel R.
AU - Elie, Cheryl M.
AU - Goetz, Matthew B.
AU - Lennox, Jeffrey L.
AU - Carlone, George M.
AU - Romero-Steiner, Sandra
AU - Holder, Patricia F.
AU - O'Brien, William A.
AU - Whitney, Cynthia G.
AU - Butler, Jay C.
AU - Breiman, Robert F.
N1 - Funding Information:
We thank Brian Plikaytis and Elizabeth Zell for statistical input, Sally Shupien and Barbara Rossman for study management at the Los Angeles site, Ericka Patrick and Marie Todd-Turner for study management at the Atlanta site, Tajel Desai and Ian Lentnek for laboratory support, and John Walls for data entry. We would like to thank Wyeth-Lederle for donation of vaccines and provision of randomization codes. This study was supported financially by The Opportunistic Infections Research Program, National Center for HIV, STD and TB Prevention, and National Center for Infectious Diseases, and the National Vaccine Program Office, Centers for Disease Control and Prevention.
PY - 2001/11/12
Y1 - 2001/11/12
N2 - In a double-blinded, randomized trial, human immunodeficiency virus (HIV)-infected adults with ≥200 CD4 cells/μl received placebo (PL), 7-valent conjugate, or 23-valent pneumococcal polysaccharide (PS) vaccine in one of the following two-dose combinations given 8 weeks apart: conjugate-conjugate, conjugate-polysaccharide, placebo-polysaccharide, placebo-placebo. A total of 67 persons completed the study. Neither significant increases in HIV viral load nor severe adverse reactions occurred in any group. After controlling for confounders, when compared with persons receiving placebo-polysaccharide, persons receiving conjugate-conjugate and conjugate-polysaccharide had higher antibody concentrations (serotypes 4, 6B, 9V and serotype 23F, respectively) and opsonophagocytic titers (functional antibody assay, serotypes 9V, 23F and serotypes 4, 6B, 9V, respectively) after the second dose (P < 0.05). The second dose with either conjugate or polysaccharide following the first conjugate dose, however, produced no further increase in immune responses. Published by Elsevier Science Ltd.
AB - In a double-blinded, randomized trial, human immunodeficiency virus (HIV)-infected adults with ≥200 CD4 cells/μl received placebo (PL), 7-valent conjugate, or 23-valent pneumococcal polysaccharide (PS) vaccine in one of the following two-dose combinations given 8 weeks apart: conjugate-conjugate, conjugate-polysaccharide, placebo-polysaccharide, placebo-placebo. A total of 67 persons completed the study. Neither significant increases in HIV viral load nor severe adverse reactions occurred in any group. After controlling for confounders, when compared with persons receiving placebo-polysaccharide, persons receiving conjugate-conjugate and conjugate-polysaccharide had higher antibody concentrations (serotypes 4, 6B, 9V and serotype 23F, respectively) and opsonophagocytic titers (functional antibody assay, serotypes 9V, 23F and serotypes 4, 6B, 9V, respectively) after the second dose (P < 0.05). The second dose with either conjugate or polysaccharide following the first conjugate dose, however, produced no further increase in immune responses. Published by Elsevier Science Ltd.
KW - Conjugate vaccines
KW - HIV
KW - Pneumococcal disease
UR - http://www.scopus.com/inward/record.url?scp=0035851352&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0035851352&partnerID=8YFLogxK
U2 - 10.1016/S0264-410X(01)00347-4
DO - 10.1016/S0264-410X(01)00347-4
M3 - Article
C2 - 11672921
AN - SCOPUS:0035851352
SN - 0264-410X
VL - 20
SP - 545
EP - 553
JO - Vaccine
JF - Vaccine
IS - 3-4
ER -